Cisplatin plus etoposide in small cell lung cancer.

No abstract is available for this paper.

• Publication year

  1988

• Venue

  Seminars in Oncology

• Publication date

  1988-06-01

• Fields of study

  Medicine

• Identifiers
  PMID 2839902
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung.

  1987cited by this paper
• High-dose induction chemotherapy with cyclophosphamide, etoposide, and cisplatin for extensive-stage small-cell lung cancer.

  1987cited by this paper
• Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada.

  1987cited by this paper
• Multicenter Phase II trial of etoposide in refractory small cell lung cancer.

  1985cited by this paper
• VP-16 and cisplatin as first-line therapy for small-cell lung cancer.

  1985cited by this paper
• Successful treatment of resistant germinal neoplasms with VP-16 and cisplatin: results of a Southeastern Cancer Study Group trial.

  1985cited by this paper
• Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small-cell lung cancer.

  1985cited by this paper
• Phase II trial of etoposide in previously treated small cell carcinoma of the lung.

  1984cited by this paper
• VP‐16 alone and in combination with cisplatin in previously treated patients with small cell lung cancer

  1984cited by this paper
• Etoposide in small cell lung cancer resistant to prior chemotherapy.

  1983cited by this paper
• Rationale for the use of alternating non-cross-resistant chemotherapy.

  1982cited by this paper
• cis-Dichlorodiammineplatinum(II) and VP-16-213: an active induction regimen for small cell carcinoma of the lung.

  1979cited by this paper
• cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice.

  1979cited by this paper
• Small-cell carcinoma of the lung: combined chemotherapy and radiation: a Southwest Oncology Group study.

  1978cited by this paper

• Comparison of oral versus intravenous etoposide in the management of small‐cell lung cancer; A real‐world, population‐based study

  2020cites this paper
• Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive‐stage small cell lung cancer: A multicentre, randomised, double‐blind, placebo‐controlled Phase II trial

  2020cites this paper
• A narrative review of salvage therapy in small cell lung cancer

  2020cites this paper
• Treatment advances in small cell lung cancer (SCLC)

  2017cites this paper
• Targeting DNA Replication Stress for Cancer Therapy

  2016cites this paper
• Phase II trial of first-line chemotherapy with gemcitabine, etoposide, and cisplatin for patients with advanced urothelial carcinoma.

  2014cites this paper
• Chemotherapy advances in small-cell lung cancer.

  2013cites this paper
• Combination of three cytotoxic agents in small-cell lung cancer

  2012cites this paper
• Therapy of small cell lung cancer with emphasis on oral topotecan.

  2010cites this paper
• Mechanisms of drug combinations: interaction and network perspectives

  2009cites this paper
• Comparison of cisplatin-paclitaxel combination versus cisplatin-etoposide in patients with small-cell lung cancer: a Phase III study.

  2008cites this paper
• Small cell lung cancer.

  2008cites this paper
• Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancer.

  2007cites this paper
• Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.

  2006cites this paper
• Inference for Mixtures of Finite Polya Tree Models

  2006cites this paper
• Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732.

  2005cites this paper
• Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer (NSCLC)

  2004cites this paper
• Pharmacodynamics of three daily infusions of etoposide in patients with extensive-stage small-cell lung cancer

  2004cites this paper
• Chemotherapy for small cell lung cancer.

  2003cites this paper
• Analysis of Prognostic Factors Related to Survival Time for Patients with Small Cell Lung Cancer

  2003cites this paper
• Concurrent Etoposide/Cisplatin Combination Chemotherapy (EP) and Thoracic Radiotherapy after Two Cycles of EP for Limited Stage Small Cell Lung Cancer.

  2002cites this paper
• Novel doublets in extensive-stage small-cell lung cancer: a randomized phase II study of topotecan plus cisplatin or paclitaxel (CALGB 9430).

  2002cites this paper
• Extensive stage small cell lung cancer

  2001cites this paper
• Evidence of a reduced DNA topoisomerase II mRNA expression after ionizing radiation.

  1999cites this paper
• Current guidelines for the management of small cell lung cancer.

  1999cites this paper
• Cisplatin plus oral etoposide in the treatment of patients with advanced small cell lung cancer. Japan Clinical Oncology Group.

  1998cites this paper
• Merkel cell carcinoma of the vulva.

  1997cites this paper
• Suramin inhibits the growth of non-small-cell lung cancer cells that express the epidermal growth factor receptor.

  1997cites this paper
• Current management of small cell lung cancer.

  1997cites this paper
• Small Cell Carcinoma of the Larynx and Ectopic Antidiuretic Hormone Secretion

  1995cites this paper
• Is carboplatin and oral etoposide an effective and feasible regimen in patients with small cell lung cancer?

  1995cites this paper
• [Localized small-cell lung cancers: prospects of concomitant radiochemotherapy].

  1995cites this paper
• Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.

  1995cites this paper
• Preservation of organ and function in the treatment of laryngeal cancer.

  1995cites this paper
• A Randomized Clinical Trial in Bronchogenic Small‐Cell Carcinoma Evaluating Alternating Maintenance Therapy of Vincristine, Adriamycin, Procarbazine, and Etoposide (VAPE) with Cyclophosphamide, CCNU, and Methotrexate (CCM) versus CCM Maintenance Alone in Complete Responders Following VAPE Induction

  1994cites this paper
• In vitro and in vivo Effects of Cisplatin and Etoposide in Combination on Small Cell Lung Cancer Cell Lines

  1994cites this paper
• Phase II trial of oral etoposide plus cisplatin in extensive stage small cell carcinoma of the lung: an Eastern Cooperative Oncology Group study.

  1994cites this paper
• Medical Treatment of Neuroendocrine Tumors

  1993cites this paper
• Pilot study of cyclophosphamide‐doxorubicin‐vincristine‐cisplatin‐etoposide hybrid chemotherapy in small cell lung cancer

  1993cites this paper
• Current perspectives in the treatment of small cell lung cancer

  1993cites this paper
• Concurrent Carboplatin (CBDCA), Vindesine (VDS) and Radiotherapy in Stage III Non Small Cell Lung Cancer (NSCLC)

  1993cites this paper
• Merkel cell carcinoma of the vulva.

  1993cites this paper
• High-dose biweekly intraperitoneal cisplatin: an effective way to increase cisplatin dose intensity.

  1993cites this paper
• Incorporation of radiotherapy fractionation in the combined-modality treatment of limited small-cell lung cancer.

  1993cites this paper
• Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group.

  1992cites this paper
• Clinical trials with ifosfamide: the Indiana University experience.

  1992cites this paper
• Etoposide, Ifosfamide, and Cisplatin in Extensive Small Cell Lung Cancer

  1992cites this paper
• Extrapulmonary and pulmonary small-cell carcinoma: tumor biology, therapy, and outcome.

  1992cites this paper
• A phase II study of the combination of carboplatin and ifosfamide in previously untreated metastatic small cell lung carcinoma

  1991cites this paper
• Chemotherapy of Metastatic Merkel Cell Carcinoma: Case Report and Review of the Literature

  1991cites this paper
• Intraperitoneal cisplatin-based chemotherapy for ovarian carcinoma.

  1991cites this paper
• A phase II trial of intraperitoneal cisplatin and etoposide for primary treatment of ovarian epithelial cancer.

  1990cites this paper
• The use of VP16 and cisplatin in the treatment of Merkel cell carcinoma.

  1990cites this paper
• Progress in the systemic treatment of cancer.Concepts, trials, drugs, and biologics

  1990cites this paper
• Recent Advances in Chemotherapy

  1990cites this paper
• Recent advances in chemotherapy. Administration and nursing implications.

  1990cites this paper
• Cisplatin for small-cell lung cancer.

  1989cites this paper
• Second line chemotherapy in small

  1989cites this paper
• Stability of cisplatin and etoposide in intravenous admixtures.

  1989cites this paper
• Second line chemotherapy in small cell lung cancer

  1989cites this paper
• Complete remission of refractory small cell carcinoma of the pancreas with cisplatin and etoposide

  1989cites this paper